Navigation Links
Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
Date:11/7/2012

certain of our other drug candidates and those of our collaboration partners.  Forward-looking statements are neither historical facts nor assurances of future performance.  Instead, they are based only on our current beliefs, expectations, observations and assumptions regarding the potential of our drug candidates and our technology. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control.  Our actual results may differ materially from those indicated in the forward-looking statements.  Therefore, you should not rely on any of these forward-looking statements.  Important factors that could cause our actual results to differ materially from those indicated in the forward-looking statements include, among others: (i) etirinotecan pegol is in clinical development and the risk of failure is high and can unexpectedly occur at any time prior to regulatory approval for numerous reasons including safety and efficacy findings; (ii) the statements regarding the therapeutic potential of etirinotecan pegol are based on preclinical data and data from the completed Phase 2 clinical study and the future results from the BEACON clinical study may not confirm these earlier findings; (iii) the timing of the commencement or end of clinical trials and the successful commercial launch of our drug candidates may be delayed or unsuccessful due to slower than anticipated patient enrollment, manufacturing challenges, changing standards of care, regulatory delay, evolving regulatory requirements, clinical trial design, clinical outcomes, competitive factors, or delay or failure in ultimately obtaining regulatory approval in one or more important markets; (iv) scientific discovery of new medical breakthroughs is an inherently uncertain process and the future success of the application of our technology
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Nektar to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the UBS 2012 Global Life Sciences Conference in New York City
3. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2012
4. Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma
5. Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
6. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
7. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2012 Global Healthcare Conference in New York
8. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
9. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
10. Life Technologies Announces Next-Gen Digital PCR Instrument Designed for Widespread Adoption
11. Blue Belt Technologies Announces First United Kingdom-Based NavioPFS Unicondylar Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... 2015 Woodford Patient Capital ... Trust and the Bill & Melinda Gates Foundation ... a leading monoclonal antibody biopharmaceutical company, announced today ... million to complete a US$90 million Series B ... Woodford Patient Capital Trust plc (LSE:WPCT,"Woodford") and Malin ...
(Date:5/5/2015)... , May 6, 2015 The ... lead the European market in the segment of animal ... alliance ECUPHAR acquires all the assets of Esteve Veterinary ... in the coming weeks. Being both private companies, the ...      (Photo: http://photos.prnewswire.com/prnh/20150506/743274 ) , ...
(Date:5/5/2015)... , May 5, 2015  In line with CBME ... to the community with a charity program to create ... autism. CBME China team is coordinating ... and maternity manufacturers, brand owners and distributors. All donated ... July 2015. Proceeds from the sale will be used ...
Breaking Medicine Technology:Kymab Secures US$90 Million Funding 2Kymab Secures US$90 Million Funding 3Kymab Secures US$90 Million Funding 4ECUPHAR Enters the Spanish and Southern European Markets Through ESTEVE 2CBME China Launches Charity Program to Support Children with Autism 2
... 2011 Researchers from Australia have identified ... factor for Autism Spectrum Disorders.  Pink disease was common in ... illness affecting children between the ages of eighteen months and ... irritability, and progressive loss of speech, symptoms very similar to ...
... CENTENNIAL, Colo., Aug. 9, 2011 AlloSource, a ... soft-tissue allografts for use in surgical procedures around ... with the Alliance for Regenerative Medicine (ARM) and ... membership with both organizations in order to support ...
Cached Medicine Technology:Familial Susceptibility to Mercury is a Risk Factor for Autism 2AlloSource Joins Alliance for Regenerative Medicine, Medical Device Manufacturers Association 2AlloSource Joins Alliance for Regenerative Medicine, Medical Device Manufacturers Association 3
(Date:5/6/2015)... 2015 Wolters Kluwer , a ... students, announced today that in a survey of nearly ... of the clinical decision support resource improves the quality ... 2014, UpToDate users in more than 170 countries worldwide ... on average. In Germany alone, 95% of all university ...
(Date:5/6/2015)... 06, 2015 Healthcare jobs ... after launching in mid-February. The company connects hospitals, home-health, ... previous experience in the industry. Likewise, job seekers are ... to Kyle Johnson, CTO, unique traffic to the site ... month: "Each new job posting brings targeted, interested candidates ...
(Date:5/6/2015)... Locally owned, Greek olive oil producer and importer, Our Family’s ... one the best Extra Virgin Olive Oils in the world. ... Greece and known as Laconiko , received the ... Oil, which is defined by the competition as “the perfect ... applicants from 25 different countries applying, Laconiko stood out as ...
(Date:5/6/2015)... 06, 2015 Dr. Vito C. Quatela, one ... , recently completed a medical mission trip to Hanoi, Vietnam ... those affected by microtia and other deformities of the face. ... and ended on April 26, Dr. Quatela and his team ... a congenital deformity where the outside of the ear is ...
(Date:5/6/2015)... Los Angeles, California (PRWEB) May 06, 2015 ... has secured its first round of VC funding and ... , The enterprise class embeddable software enables applications ... transform data as it moves between systems and locations. ... the HyperTransfer technology moves files at line speed, independent ...
Breaking Medicine News(10 mins):Health News:Current, Evidence-Based Knowledge for Physicians: UpToDate supports quick and accurate decision support for diagnosis and treatment 2Health News:Current, Evidence-Based Knowledge for Physicians: UpToDate supports quick and accurate decision support for diagnosis and treatment 3Health News:Job Seekers Turn to JobMedic to Find Healthcare Positions - JobMedic.com Reaches 1,000 User Milestone 2Health News:Greek Extra Virgin Olive Oil, Laconiko Wins Gold at the NYIOOC and Is Featured in Olive Oil Times as One of Greece's Best EVOO's for 2015 2Health News:Dr. Vito Quatela Completes Successful 10-Day Medical Mission Trip to Hanoi, Vietnam 2Health News:Dr. Vito Quatela Completes Successful 10-Day Medical Mission Trip to Hanoi, Vietnam 3Health News:TransferSoft Launches Industry’s Most Comprehensive Data Movement Technology Suite to Optimize Disaster Recovery, Big Data, and Cloud Applications 2Health News:TransferSoft Launches Industry’s Most Comprehensive Data Movement Technology Suite to Optimize Disaster Recovery, Big Data, and Cloud Applications 3Health News:TransferSoft Launches Industry’s Most Comprehensive Data Movement Technology Suite to Optimize Disaster Recovery, Big Data, and Cloud Applications 4
... New study says that how much we drink may be ... revealed that the gene called DRD2 Taq1A(C32806T) polymorphism and social ... people with a stronger gene of this type will tend ... of this gene. The gene is responsible for enhancing the ...
... study, the drug perindopril used in early treatment of ... onset and progress of left ventricle dysfunction. ... muscular dystrophies that are characterized by muscle enlargement and ... is linked with the X-chromosomes and thus affects male ...
... A research which examined the tobacco byproducts in the ... been fooling // themselves by thinking that they are ... cigarettes. ,No significant difference was found in ... regardless of the type of cigarettes they smoked nor ...
... recent study in the journal Health and Place says that mercury ... of the reasons // of rise in number of autistic children. ... of the power plants that consume coal. According to the researchers, ... into the environment, there is a 61% increase in the rate ...
... E seemed to suggest that supplementing the diet with ... //Recently, a study published In Journal Of American Medical ... may be something very different. ,The researchers ... Prevention Evaluation or HOPE centers between 1993 and 1999, ...
... the apex medical body warns the people of South East ... bird flu virus in the area. It has also ... information to WHO regarding new cases of the disease. The ... closeness in occurrence in time and place is important to ...
Cached Medicine News:
... BALLARD Adult TRACH CARE Double Swivel ... patients. Dual swivels provide flexibility without ... and tactile sleeve for better feel. ... the distance of catheter advance. Offers ...
... KIMBERLY-CLARK BALLARD Adult ... designed for endotracheal intubated ... Features clear T-Piece, lavage/irrigation ... port. Offers multiple tracheostomy ...
... Our soft, flexible whistle tip suction ... kit that includes: One pair of ... 120 ml bottle of sterile saline. ... use with cuffed gloves and catheter ...
... Irri-Cath® catheters help decrease the need ... alternative to fiber-optic bronchoscope for bronchial ... in opportunistic infections., ,All Portex® ... ,The Irri-Cath® suction system ...
Medicine Products: